Overwijk Willem W
Department of Melanoma Medical Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 904, Houston, Texas 77030, USA.
Curr Opin Immunol. 2005 Apr;17(2):187-94. doi: 10.1016/j.coi.2005.01.011.
The discovery of defined tumor antigens and their application in therapeutic cancer vaccines has not yet resulted in a successful therapy for cancer patients. Recent data suggest that this might be because most current clinical immunotherapeutic strategies rely on a tolerized tumor-reactive T-cell repertoire, resulting in a weak T-cell response that cannot induce tumor regression in the face of a multitude of normal and tumor-induced immunoregulatory mechanisms. New insights from animal models and clinical trials suggest a rationale for combination approaches in which the ineffective endogenous anti-tumor immune response is enhanced through a combination of adoptive cell transfer (ACT), specific vaccination and cytokine help for the reliable induction of a robust anti-tumor immune response and tumor regression.
已明确的肿瘤抗原的发现及其在治疗性癌症疫苗中的应用尚未为癌症患者带来成功的治疗方法。近期数据表明，这可能是因为当前大多数临床免疫治疗策略依赖于耐受的肿瘤反应性T细胞库，导致T细胞反应较弱，面对众多正常和肿瘤诱导的免疫调节机制时无法诱导肿瘤消退。动物模型和临床试验的新见解为联合治疗方法提供了理论依据，即通过过继性细胞转移（ACT）、特异性疫苗接种和细胞因子辅助的联合使用来增强无效的内源性抗肿瘤免疫反应，从而可靠地诱导强大的抗肿瘤免疫反应和肿瘤消退。
